Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Verici Dx Plc ( (GB:VRCI) ) is now available.
Verici Dx Plc announced plans to raise funds through an equity fundraising to extend its cash runway and support the commercial growth of its Tutivia™ diagnostic test, following the recent Medicare coverage approval. The company aims to achieve $3.2 million in Tutivia™ revenues for FY 2025, and the fundraising will involve a placing and a retail offer for existing shareholders, with further updates expected by the end of June.
More about Verici Dx Plc
Verici Dx Plc operates in the healthcare industry, specializing in advanced clinical diagnostics for organ transplants. The company’s primary product, Tutivia™, is a diagnostic test designed to detect acute rejection in organ transplant patients. Verici Dx focuses on expanding its market presence by securing Medicare coverage and raising funds to accelerate the commercial growth of its products.
Average Trading Volume: 1,224,332
Technical Sentiment Signal: Sell
Current Market Cap: £3.94M
For a thorough assessment of VRCI stock, go to TipRanks’ Stock Analysis page.